Novacyt boosts FY revenue by 35%

Clinical diagnostics group Novacyt said it boosted sales by 35% in 2017, with all parts of the company achieving double-digit sales growth.

The company ended the year with €4.3m (£3.8m) in cash.

"With continued organic sales growth and strong gross margins, we are aiming to move into profitable trading during 2018 to strengthen the basis for future growth," chief executive Graham Mullis said.

At 8:28am: (LON:NCYT) Novacyt S.a. Eur115th Cdi share price was +3p at 69.5p